JNJ-39758979 2HCl
| Code | Size | Price |
|---|
| TAR-T24208-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
JNJ-39758979 2HCl is an antagonist of histamine receptor H4.
CAS:
1620648-30-7
Formula:
C11H21Cl2N5
Molecular Weight:
294.22
Purity:
0.98
SMILES:
CC(c1nc(N)nc(N2CC[C@H](C2)N)c1)C.Cl.Cl
References
1. Kollmeier AP, Greenspan A, Xu XL, Silkoff PE, Barnathan E, Loza MJ, Jiang J, Zhou B, Chen B, Thurmond RL. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of an H(4) R-antagonist (JNJ-39758979) in adults with uncontrolled asthma. Clin Exp Allergy. 2018 Apr 23. doi: 10.1111/cea.13154. [Epub ahead of print] PubMed PMID: 29682796.
2. K?chling H, Schaper K, Wilzopolski J, Gutzmer R, Werfel T, B?umer W, Kietzmann M, Rossbach K. Combined treatment with H1 and H4 receptor antagonists reduces inflammation in a mouse model of atopic dermatitis. J Dermatol Sci. 2017 Aug;87(2):130-137. doi: 10.1016/j.jdermsci.2017.04.004. Epub 2017 Apr 21. PubMed PMID: 28495120.
3. Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ, Edwards JP. Clinical Development of Histamine H(4) Receptor Antagonists. Handb Exp Pharmacol. 2017;241:301-320. doi: 10.1007/164_2016_130. Review. PubMed PMID: 28233185.
4. Sulaiman I, Lim JC, Soo HL, Stanslas J. Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation. Pulm Pharmacol Ther. 2016 Oct;40:52-68. doi: 10.1016/j.pupt.2016.07.005. Epub 2016 Jul 22. Review. PubMed PMID: 27453494.